Novel drug-coated stent

Abstract

The invention discloses a novel drug-coated stent. The novel drug-coated stent comprises a stent body and a drug coating applied to the stent body, wherein the drug coating comprises drug and a drug carrier, the drug contains a tissue factor pathway inhibitor which is TFPI-1or TFPI-2, and the mass ratio of the drug to the drug carrier is 1:(8-12). The drug further contains one or two of sirolimus drug, taxol drug and statin drug. The thickness of the drug coating is 100-230 microns. The novel drug-coated stent has the advantages that stent thrombosis incidence can be reduced, the rate of recurrence of infarction and fatality rate of patients can be reduced remarkably, and long-term prognosis can be improved; usage of antiplatelet drugs and anticoagulant drugs is reduced, and the occurrence rate of bleeding events is reduced; the tissue factor pathway inhibitor is tissue factor physiological inhibitor, has high blood compatibility and histocompatibility, and is free of toxic or side effect and has few influences on human body.

Description

technical field [0001] The invention relates to a medical stent implanted in a human body, in particular to a drug-coated stent. Background technique [0002] Now percutaneous coronary intervention has become the main method of reperfusion therapy for acute myocardial infarction. Although the emergence of drug-eluting stents has greatly reduced the rate of in-stent restenosis, more and more studies have shown that drug-eluting stents have a higher risk of in-stent thrombosis than bare metal stents. At present, most of the drug-coated stents used clinically are chemical small molecule drugs, which not only inhibit the proliferation of smooth muscle, but also inhibit the growth of endothelial cells, resulting in incomplete endothelialization of the vessel wall and exposure of the cell matrix, thereby activating the coagulation reaction and increasing It reduces the incidence of stent thrombosis, a complication with high infarction rate and mortality, and brings great harm to ...

AI Technical Summary

Problems solved by technology

However, antiplatelet and anticoagulant therapy are forced to use systemic because there is no local method, and the correspondence between the two is poor

Moreover, while antiplatelet drugs and anticoagulant drugs reduce ischemic events, they also increase the risk of bleeding events. The most common ones are gastrointestinal hemorrhage and cerebral hemorrhage. heavy economic burden on patients and society

Elderly, female, underweight, and patients with renal insufficiency are especially prone to bleeding. Severe bleeding can also cause hypotension, volume depletion, and further induce ischemia. Stopping antithrombotic drugs during bleeding increases the risk of stent thrombosis, thereby increasing the risk of stent thrombosis in patients. The risk of death brings great difficulties to clinical treatment

Images